EA201490472A1 - Комбинированная терапия рака hsp90-ингибитором и антиметаболитом - Google Patents
Комбинированная терапия рака hsp90-ингибитором и антиметаболитомInfo
- Publication number
- EA201490472A1 EA201490472A1 EA201490472A EA201490472A EA201490472A1 EA 201490472 A1 EA201490472 A1 EA 201490472A1 EA 201490472 A EA201490472 A EA 201490472A EA 201490472 A EA201490472 A EA 201490472A EA 201490472 A1 EA201490472 A1 EA 201490472A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cancer
- antimetabolitis
- cancer therapy
- hsp90 inhibitor
- combined cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161525375P | 2011-08-19 | 2011-08-19 | |
| US201161555787P | 2011-11-04 | 2011-11-04 | |
| PCT/US2012/051316 WO2013028505A1 (en) | 2011-08-19 | 2012-08-17 | Combination cancer therapy of hsp90 inhibitor with antimetabolite |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201490472A1 true EA201490472A1 (ru) | 2014-05-30 |
Family
ID=46759073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201490472A EA201490472A1 (ru) | 2011-08-19 | 2012-08-17 | Комбинированная терапия рака hsp90-ингибитором и антиметаболитом |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20140296176A1 (enExample) |
| EP (1) | EP2744494A1 (enExample) |
| JP (1) | JP2014524469A (enExample) |
| AU (1) | AU2012299177A1 (enExample) |
| CA (1) | CA2844809A1 (enExample) |
| EA (1) | EA201490472A1 (enExample) |
| WO (1) | WO2013028505A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200804314A (en) | 2006-05-25 | 2008-01-16 | Synta Pharmaceuticals Corp | Triazole compounds that modulate Hsp90 activity |
| TW201011003A (en) | 2008-08-08 | 2010-03-16 | Synta Pharmaceuticals Corp | Triazole compounds that modulate HSP90 activity |
| US9205086B2 (en) | 2010-04-19 | 2015-12-08 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
| US9439899B2 (en) | 2011-11-02 | 2016-09-13 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors |
| WO2013067165A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
| US9402831B2 (en) | 2011-11-14 | 2016-08-02 | Synta Pharmaceutical Corp. | Combination therapy of HSP90 inhibitors with BRAF inhibitors |
| US20140079636A1 (en) * | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
| WO2014018862A1 (en) * | 2012-07-27 | 2014-01-30 | Corning Incorporated | Pharmaceutical compositions comprising a heat shock protein inhibitor and a|purine de novo synthesis inhibitor for treating rheumatoid arthritis or cancer |
| SMT202200285T1 (it) | 2014-08-11 | 2022-09-14 | Acerta Pharma Bv | Combinazioni terapeutiche di un inibitore di btk, un inibitore di pd-1 e/o un inibitore di pd-l1 |
| AR101504A1 (es) | 2014-08-11 | 2016-12-21 | Acerta Pharma Bv | Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6 |
| ES2900184T3 (es) | 2014-08-11 | 2022-03-16 | Acerta Pharma Bv | Combinaciones terapéuticas de un inhibidor de BTK y un inhibidor de BCL-2 |
| ES2928018T3 (es) | 2015-02-13 | 2022-11-15 | Sun Pharmaceutical Ind Ltd | Forma de dosificación para infusión intravenosa |
| CA3067463A1 (en) | 2017-06-20 | 2018-12-27 | Madrigal Pharmaceuticals, Inc. | Combination therapies comprising targeted therapeutics |
| WO2018236781A2 (en) | 2017-06-20 | 2018-12-27 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| KR20200016877A (ko) * | 2017-06-20 | 2020-02-17 | 타베다 세라퓨틱스, 인코포레이티드 | 표적 치료제를 포함하는 병용 요법 |
| CN115957328A (zh) * | 2022-07-13 | 2023-04-14 | 杭州百可生物科技有限公司 | 一种用于治疗白血病的药物组合物以及白血病的治疗方法 |
| CN121041304A (zh) * | 2025-11-06 | 2025-12-02 | 哈尔滨医科大学 | Cct018159与奈拉滨联合用药在制备急性白血病药物中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US20050020534A1 (en) * | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites |
| DK1817295T3 (da) * | 2004-11-18 | 2013-02-18 | Synta Pharmaceuticals Corp | Triazolforbindelser, der modulerer HSP90-aktivitet |
| WO2012068487A1 (en) * | 2010-11-18 | 2012-05-24 | Synta Pharmaceuticals Corp. | Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status |
-
2012
- 2012-08-17 WO PCT/US2012/051316 patent/WO2013028505A1/en not_active Ceased
- 2012-08-17 CA CA2844809A patent/CA2844809A1/en not_active Abandoned
- 2012-08-17 US US14/239,676 patent/US20140296176A1/en not_active Abandoned
- 2012-08-17 AU AU2012299177A patent/AU2012299177A1/en not_active Abandoned
- 2012-08-17 EP EP12753315.6A patent/EP2744494A1/en not_active Withdrawn
- 2012-08-17 JP JP2014527196A patent/JP2014524469A/ja not_active Withdrawn
- 2012-08-17 EA EA201490472A patent/EA201490472A1/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014524469A (ja) | 2014-09-22 |
| WO2013028505A1 (en) | 2013-02-28 |
| CA2844809A1 (en) | 2013-02-28 |
| AU2012299177A1 (en) | 2014-04-10 |
| US20140296176A1 (en) | 2014-10-02 |
| EP2744494A1 (en) | 2014-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201490472A1 (ru) | Комбинированная терапия рака hsp90-ингибитором и антиметаболитом | |
| HRP20210212T1 (hr) | Triciklični spoj kao antikancerogeni agensi | |
| WO2011112953A3 (en) | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers | |
| EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
| EA201270247A1 (ru) | Способы применения с-мет-модуляторов | |
| CY1121038T1 (el) | Θεραπεια καρκινου μαστου | |
| UA100979C2 (ru) | Применение пиридопиримидиноновых ингибиторов pi3k альфа для лечения рака | |
| WO2015154064A3 (en) | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| EA202090291A2 (ru) | Производные бипиразола в качестве ингибиторов jak | |
| CY1116231T1 (el) | ΑΛΑΤΑ ΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ 2,3-ΔIYΔPOΪMIΔAZO[l,2-C] ΚΙΝΑΖΟΛΙΝΗΣ | |
| EA201270570A1 (ru) | Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90 | |
| MX2016006919A (es) | Nucleotidos para el tratamiento de cancer de higado. | |
| EA201171415A1 (ru) | Ингибиторы белков семейства iap | |
| MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
| NZ711948A (en) | Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one | |
| MX2014003376A (es) | Derivados de acido benzoico como inhibidores eif4e. | |
| EA201391114A1 (ru) | Способы использования alk-ингибиторов | |
| MX358303B (es) | Uso de 7-(6-(2-hidroxipropan-2il) piridin-3-il)-1-((1r,4r)4-metoxi ciclohexil)-3, 4-dihidropirazin-[2,3-b] pirazin-2(1h)-ona o una sal, estereoisómero o tautómero aceptable farmaceuticamente del mismo, en combinación con una cantidad efectiva de erlotinib o azacitidina para preparar un composición farmacéutica en el tratamiento de cáncer de pulmón de cédula no pequeña, avanzado. | |
| EP3792280A3 (en) | Anti-blys antibody | |
| MX2011011083A (es) | Compuestos heterociclicos como inhibidores de mek. | |
| EA201391337A1 (ru) | Ингибиторы hsp90 | |
| MX2014005838A (es) | Morfolinilbenzotriazinas para el uso en la terapia de cancer. | |
| EA201591024A1 (ru) | Димерные соединения | |
| MX2014008864A (es) | Derivados de triazolo[4,5-d]pirimidina. |